The intestinal microbiome and the liver transplant recipient: What we know and what we need to know

Transplantation

Volumn 100, Issue 1, 2016, Pages 61-68

  Doycheva, Iliana ^a   Leise, Michael D ^b   Watt, Kymberly D ^b  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; BACTERIAL EXTRACT; BETA GLUCAN; BIFIDOBACTERIUM BREVE EXTRACT; COLISTIN; GALACTOSE OLIGOSACCHARIDE; INULIN; LACTOBACILLUS CASEI EXTRACT; LACTOBACILLUS PARACASEI EXTRACT; LACTOBACILLUS PLANTARUM EXTRACT; LEUCONOSTOC MESENTEROIDES EXTRACT; PAEDIACOCCUS PENTOSACEUS EXTRACT; PECTIN; PREBIOTIC AGENT; PROBIOTIC AGENT; RNA 16S; TOBRAMYCIN; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT;

ACTINOBACTERIA; ACUTE GRAFT REJECTION; ADAPTIVE IMMUNITY; ALCALIGENACEAE; ATHEROSCLEROSIS; BACTERIAL PERITONITIS; BACTERIAL TRANSLOCATION; BACTEROIDES; BIFIDOBACTERIUM; CARDIOVASCULAR DISEASE; CHRONIC LIVER DISEASE; CYANOBACTERIUM; DYSBIOSIS; ENTEROBACTERIACEAE; FIRMICUTES; FUSOBACTERIA; GRAFT RECIPIENT; HEPATIC ENCEPHALOPATHY; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; KIDNEY DISEASE; LACHNOSPIRACEAE; LACTOBACILLUS; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; METABOLIC DISORDER; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERIOPERATIVE PERIOD; PORPHYROMONADACEAE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEOBACTERIA; REVIEW; STREPTOCOCCUS; STREPTOCOCCUS SALIVARIUS; SYMBIONT; VEILLONELLA PARVULA; VERRUCOMICROBIA; ADVERSE EFFECTS; ANIMAL; BACTERIUM; CLASSIFICATION; GRAFT REJECTION; HOST PATHOGEN INTERACTION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INTESTINE; MICROBIOLOGY; PATHOGENICITY; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; BACTERIA; BACTERIAL TRANSLOCATION; DYSBIOSIS; GASTROINTESTINAL MICROBIOME; GRAFT REJECTION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INTESTINES; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; RISK FACTORS; TREATMENT OUTCOME;

EID: 84952631585     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001008     Document Type: Review

References (63)

1. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124:837-848.
2. Schnabl B. Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol. 2013;29:264-270.
3. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336:1268-1273.
4. Chassaing B, Etienne-Mesmin L, Gewirtz AT. Microbiota-liver axis in hepatic disease. Hepatology. 2014;59:328-339.
5. Wu X, Berkow K, Frank DN, et al. Comparative analysis of microbiome measurement platforms using latent variable structural equationmodeling. BMC Bioinformatics. 2013;14:79.
6. Purchiaroni F, Tortora A, Gabrielli M, et al. The role of intestinal microbiota and the immune system. Eur Rev Med Pharmacol Sci. 2013;17: 323-333.
7. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut. 2009;58:704-720.
8. Seki E, DeMinicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007;13:1324-1332.
9. Corbitt N, Kimura S, Isse K, et al. Gut bacteria drive Kupffer cell expansion via MAMP-mediated ICAM-1 induction on sinusoidal endothelium and influence preservation-reperfusion injury after orthotopic liver transplantation. Am J Pathol. 2013;182:180-191.
10. Chassaing B, Kumar M, Baker MT, et al. Mammalian gut immunity. Biomed J. 2014;37:246-258.
11. Bellot P, Francés R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int. 2013; 33:31-39.
12. Bauer TM, Steinbröckner B, Brinkmann FE, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol. 2001;96:2962-2967.
13. Pande C, Kumar A, Sarin SK. Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment Pharmacol Ther. 2009;29:1273-1281.
14. Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54:562-572.
15. Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513:59-64.
16. Kakiyama G, Pandak WM, Gillevet PM, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol. 2013;58:949-955.
17. Ridlon JM, Alves JM, Hylemon PB, et al. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes. 2013;4: 382-387.
18. Lorenzo-Zñiga V, Bartolí R, Planas R, et al. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology. 2003;37:551-557.
19. Bajaj JS, Ridlon JM, Hylemon PB, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 2012;302:G168-G175.
20. Llovet JM, Bartolí R, March F, et al. Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence. J Hepatol. 1998;28:307-313.
21. Zhang Z, Zhai H, Geng J, et al. Large-scale survey of gutmicrobiota associated with MHE Via 16S rRNA-based pyrosequencing. Am J Gastroenterol. 2013;108:1601-1611.
22. Zapater P, Francés R, González-Navajas JM, et al. Serum and ascitic fluid bacterial DNA: A new independent prognostic factor in noninfected patients with cirrhosis. Hepatology. 2008;48:1924-1931.
23. Shah N, Dhar D, El ZahraaMohammed F, et al. Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression. J Hepatol. 2012; 56:1047-1053.
24. Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60:940-947.
25. van Hoek B, de Rooij BJ, Verspaget HW. Risk factors for infection after liver transplantation. Best Pract Res Clin Gastroenterol. 2012;26:61-72.
26. Xie YR, Liu SL, Liu X, et al. Intestinal microbiota and innate immunityrelated gene alteration in cirrhotic rats with liver transplantation. Transplant Proc. 2011;43:3973-3979.
27. Lu H, He J, Wu Z, et al. Assessment of microbiome variation during the perioperative period in liver transplant patients: A retrospective analysis. Microb Ecol. 2013;65:781-791.
28. Wu ZW, Ling ZX, Lu HF, et al. Changes of gut bacteria and immune parameters in liver transplant recipients. Hepatobiliary Pancreat Dis Int. 2012;11:40-50.
29. Wiesner RH, Hermans PE, Rakela J, et al. Selective bowel decontamination to decrease gram-negative aerobic bacterial and Candida colonization and prevent infection after orthotopic liver transplantation. Transplantation. 1988;45:570-574.
30. Safdar N, Said A, Lucey MR. The role of selective digestive decontamination for reducing infection in patients undergoing liver transplantation: A systematic review and meta-Analysis. Liver Transpl. 2004;10:817-827.
31. Arai M, Mochida S, Ohno A, et al. Selective bowel decontamination of recipients for prevention against liver injury following orthotopic liver transplantation: evaluation with rat models. Hepatology. 1998;27: 123-127.
32. Hellinger WC, Yao JD, Alvarez S, et al. A randomized, prospective, double-blinded evaluation of selective bowel decontamination in liver transplantation. Transplantation. 2002;73:1904-1909.
33. Sun HY, Wagener M, Cacciarelli TV, et al. Impact of rifaximin use for hepatic encephalopathy on the risk of early post-Transplant infections in liver transplant recipients. Clin Transplant. 2012;26:849-852.
34. Esfeh JM, Hanouneh IA, Koval CE, et al. Impact of pretransplant rifaximin therapy on early post-liver transplant infections. Liver Transpl. 2014;20: 544-551.
35. Madsen KL, YancharNL, Sigalet DL, et al. FK506 increases permeability in rat intestine by inhibiting mitochondrial function. Gastroenterology. 1995; 109:107-114.
36. Gabe SM, Bjarnason I, Tolou-Ghamari Z, et al. The effect of tacrolimus (FK506) on intestinal barrier function and cellular energy production in humans. Gastroenterology. 1998;115:67-74.
37. Parrilli G, Abazia C, Sarnelli G, et al. Effect of chronic administration of tacrolimus and cyclosporine on human gastrointestinal permeability. Liver Transpl. 2003;9:484-488.
38. Ban K, Kozar RA. Protective role of p70S6K in intestinal ischemia/reperfusion injury in mice. PLoS One. 2012;7:e41584.
39. Xie Y, Luo Z, Li Z, et al. Structural shifts of fecal microbial communities in rats with acute rejection after liver transplantation. Microb Ecol. 2012;64: 546-554.
40. Ren Z, Jiang J, Lu H, et al. Intestinal microbial variation may predict early acute rejection after liver transplantation in rats. Transplantation. 2014; 98:844-852.
41. Hardy H, Harris J, Lyon E, Beal J, Foey AD. Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology. Nutrients. 2013;5:1869-1912.
42. Bindels LB, Delzenne NM, Cani PD, et al. Towards a more comprehensive concept for prebiotics. Nat Rev Gastroenterol Hepatol. 2015;12:303-310.
43. de Vrese M, Marteau PR. Probiotics and prebiotics: effects on diarrhea. J Nutr. 2007;137(3 Suppl 2):803S-811S.
44. Shimizu K, Ogura H, Asahara T, et al. Probiotic/synbiotic therapy for treating critically ill patients from a gut microbiota perspective. Dig Dis Sci. 2013;58:23-32.
45. Rayes N, Seehofer D, Hansen S, et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: A controlled trial in liver transplant recipients. Transplantation. 2002;74:123-127.
46. Rayes N, Seehofer D, Theruvath T, et al. Supply of pre-And probiotics reduces bacterial infection rates after liver transplantation-A randomized, double-blind trial. Am J Transplant. 2005;5:125-130.
47. Eguchi S, Takatsuki M, Hidaka M, et al. Perioperative synbiotic treatment to prevent infectious complications in patients after elective living donor liver transplantation: A prospective randomized study. Am J Surg. 2011; 201:498-502.
48. Ren ZG, Liu H, Jiang JW, et al. Protective effect of probiotics on intestinal barrier function in malnourished rats after liver transplantation. Hepatobiliary Pancreat Dis Int. 2011;10:489-496.
49. Xie Y, Chen H, Zhu B, et al. Effect of intestinal microbiota alteration on hepatic damage in rats with acute rejection after liver transplantation. Microb Ecol. 2014;68:871-880.
50. Xing HC, Li LJ, Xu KJ, et al. Protective role of supplement with foreign Bifidobacterium and Lactobacillus in experimental hepatic ischemiareperfusion injury. J Gastroenterol Hepatol. 2006;21:647-656.
51. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143:913-916.e7 e917.
52. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761-1772.
53. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541-546.
54. Xiao S, Fei N, Pang X, et al. A gut microbiota-Targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome. FEMS Microbiol Ecol. 2014;87:357-367.
55. TangWH, Wang Z, Levison BS, et al. Intestinalmicrobial metabolismof phosphatidylcholine and cardiovascular risk.NEngl J Med. 2013;368:1575-1584.
56. Andrade-Oliveira V, Amano MT, Correa-Costa M, et al. Gut bacteria products prevent AKI induced by ischemia-reperfusion. J Am Soc Nephrol. 2015;26:1877-1888.
57. Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13:800-812.
58. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877-1887.
59. Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482: 179-185.
60. Tabibian JH, O'Hara SP, Lindor KD. Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. Scand J Gastroenterol. 2014;49:901-908.
61. Henao-Mejia J, Elinav E, Thaiss CA, et al. Role of the intestinalmicrobiome in liver disease. J Autoimmun. 2013;46:66-73.
62. Zhang HL, Yu LX, Yang W, et al. Profound impact of gut homeostasis on chemically-induced pro-Tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol. 2012;57:803-812.
63. Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499:97-101.